By Health News Canada
KIRKLAND, QC, May 9 /CNW Telbec/ – A real-world study evaluating the safety of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Recombinant Vaccine] among 189,629 females in California found no serious adverse events related to vaccination, no safety signals for any health event resulting in an emergency room visit or hospitalization and no safety signals associated with pre-specified autoimmune conditions or pregnancy outcomes. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Lisbon, Portugal, May 8-12, 2011.
Among the attendants and presenters at the EUROGIN scientific sessions is Dr. Michel Roy, professor in the Department of Obstetrics and Gynaecology at Laval University in Quebec City. “The data from this large US study supports what the international clinical trials found: the quadrivalent HPV vaccine has a good safety profile. Available in Canada since 2006, the vaccine has been studied and used for about a decade now. The new safety data are reassuring especially regarding autoimmune and neurologic conditions.”
“This is a very helpful study that should lay to rest any lingering concerns regarding safety of the quadrivalent HPV vaccine. It is particularly relevant because it is a “real -world” test in a very large population, with good follow up” said Dr. Jennifer Blake, Professor and Associate Chair, Department of Obstetrics and Gynaecology, Faculty of Medicine, University of Toronto, presently onsite in Lisbon. “Many people have been asking for exactly this sort of evidence before getting vaccinated, or advising others to get vaccinated against HPV. This study answers that question.”
About the study
The observational database study of 189,629 females provided safety data on all females who received at least one dose of GARDASIL® at two large managed care organizations in California between August 2006 and March 2008. The study evaluated three main areas: general safety, including post-vaccination emergency room (ER) visits and hospitalizations; new onset of 16 pre-specified autoimmune conditions among all females; and pregnancy outcomes among females with inadvertent vaccination with the quadrivalent HPV vaccine during pregnancy.
General safety outcomes were evaluated by comparing the incidence of ER or hospital electronic diagnosis codes shortly after vaccination to the incidence in a post-vaccination self-comparison period, using conditional logistic regression.
[Note from SaneVax: One has to wonder exactly how valuable data examined from emergency room and hospital visits can be considering the fact that healthy vaccinated or unvaccinated people would not be visiting thes two types of facilities. They would be going to their own medical practitioners – usually in clinics, not hospitals or emergency rooms. This ‘study’ compared people only in the two places patients turn to when they are in dire need. Comparing these two cohorts does not take into account the thousands of healthy people undergoing their normal routine check-ups. How can anyone in their right mind say this data demonstrates a safety profile?]